JP2009519961A5 - - Google Patents

Download PDF

Info

Publication number
JP2009519961A5
JP2009519961A5 JP2008545882A JP2008545882A JP2009519961A5 JP 2009519961 A5 JP2009519961 A5 JP 2009519961A5 JP 2008545882 A JP2008545882 A JP 2008545882A JP 2008545882 A JP2008545882 A JP 2008545882A JP 2009519961 A5 JP2009519961 A5 JP 2009519961A5
Authority
JP
Japan
Prior art keywords
glp
poly
polymer complex
polymer
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008545882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519961A (ja
JP5096363B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/048181 external-priority patent/WO2007075534A2/en
Publication of JP2009519961A publication Critical patent/JP2009519961A/ja
Publication of JP2009519961A5 publication Critical patent/JP2009519961A5/ja
Application granted granted Critical
Publication of JP5096363B2 publication Critical patent/JP5096363B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008545882A 2005-12-16 2006-12-18 Glp−1のポリマ複合体 Expired - Fee Related JP5096363B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75108205P 2005-12-16 2005-12-16
US75112105P 2005-12-16 2005-12-16
US60/751,082 2005-12-16
US60/751,121 2005-12-16
PCT/US2006/048181 WO2007075534A2 (en) 2005-12-16 2006-12-18 Polymer conjugates of glp-1

Publications (3)

Publication Number Publication Date
JP2009519961A JP2009519961A (ja) 2009-05-21
JP2009519961A5 true JP2009519961A5 (https=) 2010-01-28
JP5096363B2 JP5096363B2 (ja) 2012-12-12

Family

ID=38039133

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545882A Expired - Fee Related JP5096363B2 (ja) 2005-12-16 2006-12-18 Glp−1のポリマ複合体

Country Status (5)

Country Link
US (2) US8293869B2 (https=)
EP (2) EP2364735A3 (https=)
JP (1) JP5096363B2 (https=)
ES (1) ES2390286T3 (https=)
WO (1) WO2007075534A2 (https=)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
US20120225033A1 (en) 2010-11-24 2012-09-06 Durect Corporation Biodegradable Drug Delivery Composition
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
US7851565B2 (en) 2004-12-21 2010-12-14 Nektar Therapeutics Stabilized polymeric thiol reagents
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
EP2364735A3 (en) 2005-12-16 2012-04-11 Nektar Therapeutics Branched PEG conjugates of GLP-1
IN2015DN00888A (https=) 2006-02-22 2015-07-10 Mannkind Corp
EP3222142A1 (en) 2006-02-28 2017-09-27 Kodiak Sciences Inc. Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
EP2114458B1 (en) * 2006-12-27 2014-02-26 Nektar Therapeutics Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage
JP5606738B2 (ja) 2006-12-27 2014-10-15 ウェルズ ファーゴ バンク ナショナル アソシエイション 解離可能な連結を有する第ix因子部分−ポリマー共役体
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
CA2689909C (en) 2007-06-08 2016-04-05 Ascendis Pharma As Long-acting polymeric prodrugs of exendin
JP2011500850A (ja) * 2007-10-24 2011-01-06 マンカインド コーポレイション Glp−1による副作用を防止する方法
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
MX344559B (es) 2008-04-29 2016-12-20 Ascendis Pharma As Compuestos de hormona de crecimiento humana recombinante unidos al peg.
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
KR101628410B1 (ko) 2008-06-20 2016-06-08 맨카인드 코포레이션 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
WO2010014258A2 (en) 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010033221A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of protegrin peptides
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CN104721825B (zh) 2009-06-12 2019-04-12 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
JP5980466B2 (ja) * 2009-11-13 2016-08-31 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン及びメトホルミンへの付加療法を含む2型糖尿病の治療方法
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MX337432B (es) 2009-12-15 2016-03-04 Ascendis Pharma As Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero.
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
EP2590997B1 (en) * 2010-07-09 2018-04-04 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
WO2012054822A1 (en) * 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
WO2012054861A1 (en) * 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102786590A (zh) * 2011-05-19 2012-11-21 江苏豪森药业股份有限公司 分枝型peg修饰的glp-1类似物及其可药用盐
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
KR101357117B1 (ko) 2011-06-28 2014-02-06 비앤엘델리팜 주식회사 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
EP2750681B1 (en) * 2011-08-30 2020-05-27 Quanta Biodesign, Ltd. Branched discrete peg constructs
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
EP2782590A4 (en) 2011-11-23 2016-08-03 Durect Corp BIODEGRADABLE AND MEDIUM-RADIATED STERILIZED MEDICAMENTAL COMPOSITIONS
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
SG11201703870UA (en) 2014-11-18 2017-06-29 Ascendis Pharma Endocrinology Div As Novel polymeric hgh prodrugs
PT3220892T (pt) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Formas de dosagem de hormona do crescimento de longa ação
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
WO2017062832A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
CN108697768B (zh) 2015-12-23 2022-07-22 约翰霍普金斯大学 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EA201892260A1 (ru) 2016-04-07 2019-03-29 Дзе Джонс Хопкинс Юниверсити Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス,インコーポレイティド Glp-1受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
KR20190125310A (ko) 2017-03-10 2019-11-06 퀴아펙 파마슈티칼스 에이비 방출가능한 접합체
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
CA3112473A1 (en) * 2018-09-12 2020-03-19 Quiapeg Pharmaceuticals Ab Releasable glp-1 conjugates
WO2020077289A2 (en) * 2018-10-11 2020-04-16 Nektar Therapeutics Method of making releasable polymeric reagents
CN111269309B (zh) * 2018-12-04 2022-03-08 翰宇药业(武汉)有限公司 一种glp-1类似多肽的纯化方法
CA3129576A1 (en) * 2019-02-11 2020-08-20 Opko Biologics Ltd. Long-acting glp-2 analogs
AU2020233198B2 (en) 2019-03-04 2025-05-15 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022025141A2 (pt) * 2020-06-09 2023-04-25 Vectivbio Ag Fabricação, formulação e dosagem de apraglutida

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
GB8314308D0 (en) 1983-05-24 1983-06-29 Matburn Holdings Ltd Medical administration devices
US4805811A (en) * 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
AT387234B (de) * 1987-03-05 1988-12-27 Vogelbusch Gmbh Vorrichtung zur zuechtung von dauerformen insbesondere filamentoeser mikroorganismen
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
GB8909891D0 (en) 1989-04-28 1989-06-14 Riker Laboratories Inc Device
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
IT1243344B (it) 1990-07-16 1994-06-10 Promo Pack Sa Inalatore plurimonodose per medicamenti in polvere
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DE69230613T2 (de) 1991-07-02 2000-12-28 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5470949A (en) * 1992-12-15 1995-11-28 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for making amino acid glycosides and glycopeptides
US5672581A (en) * 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
US5512459A (en) * 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5523549A (en) * 1994-05-25 1996-06-04 Ceramic Powders, Inc. Ferrite compositions for use in a microwave oven
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5522385A (en) * 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5826633A (en) 1996-04-26 1998-10-27 Inhale Therapeutic Systems Powder filling systems, apparatus and methods
IL128332A0 (en) * 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US5908830A (en) * 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69732572T2 (de) 1996-11-12 2005-12-29 Novo Nordisk A/S Verwendung von glp-1 peptiden
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
AU756693B2 (en) 1997-09-29 2003-01-23 Novartis Ag Stabilized bioactive preparations and methods of use
EP1049486A4 (en) 1997-12-05 2006-01-04 Lilly Co Eli GLP-1 FORMULATIONS
JP2002506792A (ja) * 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ N末端修飾glp−1誘導体
JP4078032B2 (ja) * 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル,コーポレイション 近位の反応性基を持つポリ(エチレングリコール)誘導体
US6257233B1 (en) * 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
BR9913284A (pt) 1998-08-28 2001-05-15 Lilly Co Eli Métodos para administrar peptìdeos insulinotrópicos
US6720407B1 (en) * 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
JP2002524514A (ja) * 1998-09-17 2002-08-06 イーライ・リリー・アンド・カンパニー タンパク質製剤
EP1992641A3 (en) 1998-12-07 2009-07-29 Ipsen Pharma GLP-1 analogues
ES2278589T3 (es) 1999-01-14 2007-08-16 Amylin Pharmaceuticals, Inc. Excendinas destinadas a la inhibicion de glucagon.
CA2372214A1 (en) 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
KR100345214B1 (ko) 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6376470B1 (en) 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
NZ518401A (en) 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
JP4142569B2 (ja) 2001-06-22 2008-09-03 協和醗酵工業株式会社 軟膏剤
EP1432430A4 (en) * 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
EP1446438A2 (en) * 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
ES2280596T3 (es) * 2001-12-29 2007-09-16 Novo Nordisk A/S Uso combinado de un compuesto de glp-1 y un inhibidor de una aldosa reductasa.
AU2003200839B2 (en) 2002-01-08 2008-12-11 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
ES2304501T3 (es) 2002-02-15 2008-10-16 Nektar Therapeutics Al, Corporation Polimeros a base de oxido de alquileno degradables hidroliticamente.
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2002950136A0 (en) 2002-07-11 2002-09-12 La Trobe University N-methyl amino acids
JP2006501820A (ja) 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾glp−1受容体アゴニストおよびそれらの薬理学的使用法
KR20050093856A (ko) 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체 알카날
ATE412684T1 (de) 2002-09-09 2008-11-15 Nektar Therapeutics Al Corp Verfahren zur herstellung von wasserlöslichen polymerderivaten mit terminalen carboxylgruppen
WO2004029081A2 (en) 2002-09-25 2004-04-08 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency
GB0223424D0 (en) 2002-10-09 2002-11-13 Imp College Innovations Ltd Disease-associated gene
JP4490369B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ,コーポレイション マレアミド酸ポリマー誘導体及びこれらの生物学的複合体
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
DE60322111D1 (de) 2002-12-31 2008-08-21 Nektar Therapeutics Al Co Verfahren zur herstellung von hydrogelen aus thiosulfonat-zusammensetzungen und ihre verwendungen
EP1581260B1 (en) 2002-12-31 2014-09-17 Nektar Therapeutics Polymeric reagents comprising a ketone or a related functional group
KR101207247B1 (ko) 2003-01-06 2012-12-03 넥타르 테라퓨틱스 티올-선택성 수용성 중합체 유도체
DE602004025205D1 (de) 2003-02-19 2010-03-11 Ipsen Pharma Glp-1-analoga
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
JP2006520818A (ja) * 2003-03-19 2006-09-14 イーライ リリー アンド カンパニー ポリエチレングリコール結合glp−1化合物
PL1620118T3 (pl) * 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
EP2644206B1 (en) * 2003-05-23 2019-04-03 Nektar Therapeutics PEG derivatives containing two PEG chains
WO2005014049A2 (en) * 2003-08-08 2005-02-17 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
BR122019021416A2 (https=) 2003-09-19 2019-12-21
US20050118718A1 (en) * 2003-09-22 2005-06-02 University Of Utah Research Foundation Stabilization and controlled delivery of ionic biopharmaceuticals
JP2007536214A (ja) 2003-12-16 2007-12-13 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Glp−1類似体
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
CA2940803A1 (en) 2004-03-23 2005-10-27 Ascendis Pharma Gmbh Prodrug linker
WO2005097158A1 (en) 2004-03-29 2005-10-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Amphipathic glycopeptides
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
RU2527893C2 (ru) 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
WO2006091506A2 (en) 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y4 receptor agonists
CA2608311C (en) 2005-05-13 2012-11-27 Eli Lilly And Company Glp-1 pegylated compounds
HUE025208T2 (en) * 2005-06-16 2016-03-29 Nektar Therapeutics Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
WO2007061148A1 (en) * 2005-11-24 2007-05-31 Pegsphere Co., Ltd. Site-specific peg conjugates of glp-1 and methods for production thereof
EP2364735A3 (en) 2005-12-16 2012-04-11 Nektar Therapeutics Branched PEG conjugates of GLP-1

Similar Documents

Publication Publication Date Title
JP2009519961A5 (https=)
Shojaei et al. Transbuccal delivery of acyclovir (II): feasibility, system design, and in vitro permeation studies
Shojaei Buccal mucosa as a route for systemic drug delivery: a review
JP5823125B2 (ja) ヒドロキシアパタイト標的化多腕ポリマーならびに、このポリマーから作られるコンジュゲート
AU725283B2 (en) Bioadhesive pharmaceutical composition for the controlled release of active principles
EP2429497B1 (en) Process for preparing microparticles
AU2010277556B2 (en) Biodegradable polyethylene glycol based water-insoluble hydrogels
Smith et al. Macromolecular (pro) drugs in antiviral research
JP2007529539A5 (https=)
EP1146861A1 (en) Hydrogel particle formulations
JP2010537008A5 (https=)
WO2007095600A3 (en) Disintegrable oral films
KR20090118953A (ko) 올리고머―항히스타민제 컨주게이트
Raju et al. Formulation and in-vitro evaluation of buccal tablets of metoprolol tartrate
WO2002064148A2 (en) Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
CN101642573A (zh) 一种壳聚糖基肝靶向纳米粒子给药系统及其制备方法
WO2007131193A3 (en) Main chain acid-degradable polymers for the delivery of bioactive materials
RU2010149561A (ru) Твердое лекарственное средство с замедленным высвобождением действующих веществ
WO2005055980A3 (en) Polymalic acid-based multifunctional drug delivery system
ES2399166T3 (es) Formulaciones tópicas antivíricas en la forma de un gel bio-adhesivo
Verma et al. Preparation of mucoadhesive patches for buccal administration of metoprolol succinate: in vitro and in vivo drug release and bioadhesion
JP2010520184A5 (https=)
CN102416000A (zh) 一种用于肺吸入的壳聚糖季铵盐大孔微球及其制备方法
Wang et al. Nanomedicine-based treatment: An emerging therapeutical strategy for pulmonary hypertension
US20110195912A1 (en) Oligomer-Protease Inhibitor Conjugates